Recent advances in the understanding of the molecular basis of gliomagenesis have led to the development of therapies which target tumor angiogenesis via inhibition of vascular endothelial growth factor (VEGF) [4] and its receptors (VEGFRs) [5,6]. Here, VEGFA is linked to neoplasm.